Joshi, A., Noronha, V., Patil, V. M., Chougule, A., Bhattacharjee, A., Kumar, R., . . . Prabhash, K. (2017). Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation? Chemother Res Pract.
Citação norma ChicagoJoshi, Amit, et al. "Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ From Exon 21 Mutation?" Chemother Res Pract 2017.
Deismireacht MLAJoshi, Amit, et al. "Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ From Exon 21 Mutation?" Chemother Res Pract 2017.
Rabhadh: D'fhéadfadh nach mbeadh na deismireachtaí seo 100% cruinn i gcónaí.